Products - Lipid disorders | Topic | NICE

Showing 21 products

Date | Title

Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 September 2024
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (TA961)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2024
Sebelipase alfa for treating Wolman disease (HST30)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
10 January 2024
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
Product type:
Guidance
Programme:
NICE guideline
Published:
14 December 2023
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2022
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 October 2021
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 April 2021
Metreleptin for treating lipodystrophy (HST14)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
24 February 2021
Familial hypercholesterolaemia: identification and management (CG71)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
4 October 2019
Published:
27 August 2008
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2016
Cardiovascular risk assessment and lipid modification (QS100)
Product type:
Quality standard
Last updated:
24 May 2023
Published:
4 September 2015
Familial hypercholesterolaemia (QS41)
Product type:
Quality standard
Last updated:
2 November 2017
Published:
13 August 2013
Cardiovascular risk assessment and lipid modification
Status:
In development
Expected publication date:
23 July 2025
VTS-270 for treating Niemann-Pick type C1 [ID1267]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venglustat for treating gangliosidoses in people 2 years and over ID 6358
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia [ID6519]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC